November 27, 2020

The Niche

Knoepfler lab stem cell blog

Athersys

5 min read

Many are  jumping on the bandwagon of trying stem cells for COVID-19 or testing other cellular therapies for the novel coronavirus disease, but there have been problems with either the rationales for the trials themselves or more often with how they portrayed. Sometimes there has even been outright hype. I’ve called this collective trend of promotion of scads of trials of cell therapies for COVID “throwing spaghetti at the wall”. Some may stick, but most probably won’t. If fact, there’s a reasonable possibility that …Read More

4 min read

Katie Thomas at the New York Times reports that BARDA has dropped considering funding applications for stem cells for COVID-19. The move is part of a larger shift in funding priorities away from lung treatments and toward vaccine development. The decision has puzzled and even angered some stem cell firms and researchers. BARDA stands for Biomedical Advanced Research and Development Authority. It has become a core decision maker related to funding for COVID-19. The BARDA shift can be found in a few notices such …Read More

5 min read

The term Regenerative Medicine covers so much biomedical science these days including everything from just about any kind of cell therapy (not just stem cells) to CRISPR gene editing, and with the the COVID-19 pandemic, it seems this umbrella use of the term now includes potential treatment of viral illnesses. It can be hard to keep track of it all. I’m regularly doing a kind of “regenerative medicine” digest these days to help. Today’s post is just such an aggregate with a focus on …Read More

10 min read

The idea of testing stem cells for COVID-19 may be music to the ears of some folks as an opportunity, but to me from the beginning it sounded mostly like a spaghetti on the wall road to trouble. There is buzz out there that some kind of stem cells or other cells will help with COVID-19. The reality is that that’s probably not going to happen. Even so, a whole range of people and firms are somewhat exaggerating and in a few cases outright …Read More